Abstract
Thrombosis, the localized clotting of blood that affects arterial or venous circulation, is one of the leading causes of death worldwide. Arterial thrombosis is commonly initiated by vascular endothelial injury, while venous thrombosis mainly stems from blood stasis. Despite these differences, platelet adhesion, activation and aggregation, and fibrin formation as a result of coagulation constitute the fundamental processes of thrombus formation. Antithrombotic drugs permitted on the clinical currently can dramatically reduce major adverse cardiovascular events; however, they can also increase the bleeding risk. Discovery of antithrombotic drugs that can effectively prevent thrombosis while sparing bleeding side effects remains unmet medical need. In this chapter, we provide an overview on the pathophysiology of thrombosis, followed by introduction of each class of antithrombotic drugs including their pharmacology, clinical applications and limitations. Practical challenges and future perspectives of antithrombotic drugs are discussed in the last part of this chapter.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Agnelli G et al (2013a) Apixaban for extended treatment of venous thromboembolism. N Engl J Med 368(8):699–708
Agnelli G et al (2013b) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369(9):799–808
Ansell J et al (2008) Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(6 Suppl):160S–198S
Bowman L et al (2018) Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. N Engl J Med 379(16):1529–1539
Büller HR et al (2004) Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 140(11):867–873
Büller HR et al (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366(14):1287–1297
Elia E et al (2019) Update on pathological platelet activation in coronary thrombosis. J Cell Physiol 234(3):2121–2133
Garcia DA et al (2012) Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e24S–e43S
Garcia D et al (2013) Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants. J Thromb Haemost: JTH 11(2):245–252
Gaziano JM et al (2018) Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet (Lond, Engl) 392(10152):1036–1046
Graham DJ et al (2015) Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 131(2):157–164
Graham DJ et al (2016) Stroke, bleeding, and mortality risks in elderly Medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation. JAMA Intern Med 176(11):1662–1671
Guirgis M, Thompson P, Jansen S (2017) Review of aspirin and clopidogrel resistance in peripheral arterial disease. J Vasc Surg 66(5):1576–1586
Holbrook A et al (2012) Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e152S–e184S
Huish S, Thelwell C, Longstaff C (2017) Activity regulation by fibrinogen and fibrin of streptokinase from Streptococcus pyogenes. PloS one 12(1):e0170936.
Jaax ME, Greinacher A (2012) Management of heparin-induced thrombocytopenia. Expert Opin Pharmacother 13(7)
Longstaff C, Williams S, Thelwell C (2008) Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem 6(3):212–223
Mega JL, Simon T (2015) Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments. Lancet (Lond, Engl) 386(9990):281–291
Melandri G et al (2009) Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. Vasc Health Risk Manag 5(1):249–256
Quinlan DJ, McQuillan A, Eikelboom JW (2004) Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials. Ann Intern Med 140(3):175–183
Silva, MMCG et al. (2012) Regulation of fibrinolysis by C-terminal lysines operates through plasminogen and plasmin but not tissue-type plasminogen activator. J Thromb Haemost: JTH 10(11):2354–2360
Simpson D et al (2006) Reteplase: a review of its use in the management of thrombotic occlusive disorders. Am J Cardiovasc Drugs: Drugs, Devices, Other Interv 6(4):265–285
Simpson D et al (2007) Spotlight on reteplase in thrombotic occlusive disorders. BioDrugs: Clin Immunother, Biopharm Gene Ther 21(1):65–68
Southworth MR, Reichman ME, Unger EF (2013) Dabigatran and postmarketing reports of bleeding. N Engl J Med 368(14):1272–1274
Thelwell C, Longstaff C (2014) Biosimilars: the process is the product. The example of recombinant streptokinase. J Thromb Haemost: JTH 12(8):1229–1233
Warkentin TE et al (2005) Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 106(12):3791–3796
Warkentin TE et al (2010) Anti-PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of non-drug risk factors and evidence for a stoichiometry-based model of immunization. J Thromb Haemost: JTH 8(3):504–512
Wiviott SD, Steg PG (2015) Clinical evidence for oral antiplatelet therapy in acute coronary syndromes. Lancet (Lond, Engl) 386(9990):292–302
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Li, T., Yuan, D., Yuan, J. (2020). Antithrombotic Drugs—Pharmacology and Perspectives. In: Wang, M. (eds) Coronary Artery Disease: Therapeutics and Drug Discovery. Advances in Experimental Medicine and Biology, vol 1177. Springer, Singapore. https://doi.org/10.1007/978-981-15-2517-9_4
Download citation
DOI: https://doi.org/10.1007/978-981-15-2517-9_4
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-15-2516-2
Online ISBN: 978-981-15-2517-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)